Powered by

Home Top Stories

Serum Sets Covishield Price For States, Private Hospitals

The Serum Institute of India (CII) has made the vaccine prices public after allowing the central government's state governments

By Ground Report
New Update
Oxford's 'Covidshield' vaccine production in India begins

The Serum Institute of India (CII) has made the vaccine prices public after allowing the central government's state governments and private hospitals to purchase the vaccine directly from the vaccine manufacturers.

CII tweeted, praising the decision of the Central Government that in the next two months it will increase the production of vaccine in limited quantity, out of which 50% will be for the Government of India and the remaining 50% will be provided by the State Governments and Private Hospitals.

ALSO READ: “It’s Time To End America’s Longest War”: Joe Biden Details Timeline To Pull Troops From Afghanistan

AstraZeneca and Oxford's vaccine is produced under the name CII covishield. CII has kept a dose of Rs 400 for state governments and Rs 600 for private hospitals.

At the same time, the company has compared the prices of the foreign vaccine to the price of the Indian vaccine. The CII has said that the cost of the American vaccine is 1500 rupees, the Russian vaccine costs 750 rupees and the Chinese vaccine costs 750 rupees.

Along with this, CII has asked corporate and private companies to get the vaccine from the government machinery and private health system. The vaccine will be available in the market in the next four-five months.

ALSO READ: Hospitals Overwhelmed, Graveyards Overflowing As Covid-19 Infections Surge In India

CII is giving a dose of covishield to the Central Government for 150 rupees which will continue to be given in the same way.

The central government had allowed vaccination of covid-19 for people over 18 years of age from 1 May, after which the central government also allowed state governments and private hospitals to purchase the vaccine themselves.

At the same time, the Government of India has announced a grant amount of Rs 4,500 crore to CII and Covaxin manufacturing company Bharat Biotech.

ALSO READ: 20-30% Covid-19 infected people lose natural immunity against infection in 6 months: Study

CII chief Adar Poonawala has said that vaccine production will pick up and by the end of May there will be 15-20% more covishields in the market.

Poonawala has said that his company will be able to produce 100 million doses every month after July.

You can connect with Ground Report on FacebookTwitter and Whatsapp, and mail us at [email protected] to send us your suggestions and writeups.